Clin2
NCT06231966Possibly a fitRecruiting

High-dose statin combo vs. standard statin for artery disease

Peripheral Artery DiseasePolyvascular Disease

Part of Heart & circulation clinical trials.

This trial compares a high-dose combination of rosuvastatin (a statin) and ezetimibe (another cholesterol-lowering drug) versus a standard rosuvastatin-only approach for people with peripheral artery disease (narrowed leg arteries) or widespread artery disease. The goal is to see which strategy better lowers LDL cholesterol and reduces heart and limb risks.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
2,462 people
Ages
19 years to 80 years
Study type
Interventional

Who can take part

  • You are between 19 and 80 years old.
  • You have blocked or narrowed arteries in your legs (like pain when walking) or in at least two other major blood vessel areas (like heart, neck, or aorta).
  • You are not currently taking cholesterol medicine, or your LDL cholesterol level is above 70 mg/dL.
  • You do not have a severe leg condition that threatens the limb, and you have not had a heart attack, stroke, or leg amputation in the last 6 months.
  • You do not have severe liver or kidney problems, and you are not allergic to statins or ezetimibe.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06186037Recruiting· Phase 4
Lower-dose combo vs. higher-dose alone for heart artery disease

This trial compares a lower-dose cholesterol pill (rosuvastatin plus ezetimibe) to a higher-dose version of just rosuvastatin for people with mild to moderate heart artery blockages who have not had a stent or bypass. It aims to see which approach works better and is safer.

Suwon, Gyeonggi-do
NCT06767774Recruiting· Phase 4
Comparing two cholesterol treatments for heart patients

This study compares two different ways of lowering cholesterol: a moderate statin (pitavastatin) plus another drug (ezetimibe) versus a stronger statin alone. The goal is to see which approach is safer regarding the risk of developing new diabetes.

Seoul
NCT07524101Recruiting
Statin and Ezetimibe for Heart Disease and Kidney Disease

This trial tests whether taking a moderate-strength statin (cholesterol-lowering drug) plus ezetimibe (another cholesterol medicine) together helps protect the heart and kidneys in people who have both chronic kidney disease and established heart disease or stroke history.

Seoul
NCT05579626Enrolling by invitation· Phase 4
Low-dose statin plus ezetimibe vs high-dose statin for prediabetes

This trial compares two cholesterol-lowering approaches in people with prediabetes to see which one is less likely to lead to new-onset diabetes. It may help you choose a safer medication plan if you need strong cholesterol treatment to prevent future heart problems.

Bucheon-si
NCT04499859Recruiting· Phase 4
Low-dose cholesterol medicines versus high-dose after heart attack

This study compares two cholesterol treatment approaches after a heart attack: a lower dose combination versus a higher dose single medicine. It aims to see which option works well and is tolerable for people after a treated heart attack.

Bucheon-si, Gyeonggido
NCT05782777Recruiting
Cholesterol medicines after stent: combo pill vs single pill

This trial compares two cholesterol-lowering treatment plans after a heart procedure where new drug-eluting stents were placed: a combination of high-intensity statin plus ezetimibe versus high-intensity statin alone. It may help find which option lowers cholesterol more effectively and safely over the first year after the procedure.

Seoul

Hear when a new Peripheral Artery Disease trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.